These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19552492)

  • 21. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
    Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
    CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jan; 128(3):294-7. PubMed ID: 18264153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic management of Alzheimer disease.
    Downey D
    J Neurosci Nurs; 2008 Feb; 40(1):55-9. PubMed ID: 18330411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
    McDermott CL; Gray SL
    Ann Pharmacother; 2012 Apr; 46(4):599-605. PubMed ID: 22414791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acetylcholinesterase inhibitors for dementia--an update].
    Anghelescu I; Heuser I
    MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
    Alisky JM
    J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
    [No Abstract]   [Full Text] [Related]  

  • 36. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.
    Raschetti R; Maggini M; Sorrentino GC; Martini N; Caffari B; Vanacore N
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):361-8. PubMed ID: 15912389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Dunbar F; Zhu Y; Brashear HR
    Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
    Seitz DP; Gill SS; Gruneir A; Austin PC; Anderson G; Reimer CL; Rochon PA
    Am J Geriatr Psychiatry; 2011 Sep; 19(9):803-13. PubMed ID: 21873836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cholinesterase inhibitor therapy in long term care settings].
    Vantelon C; Gilbert S; Kerneis S; Wolmark Y; Legrain S; Kergoat MJ
    Rev Med Interne; 2006 Aug; 27(8):588-94. PubMed ID: 16806591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.